Major Estimate Revision • May 06
Consensus EPS estimates fall by 15% The consensus outlook for fiscal year 2026 has been updated. 2026 EPS estimate fell from CN¥2.00 to CN¥1.71 per share. Revenue forecast steady at CN¥22.0b. Net income forecast to grow 4.5% next year vs 13% growth forecast for Healthcare industry in China. Consensus price target down from CN¥21.70 to CN¥21.08. Share price was steady at CN¥16.74 over the past week. Reported Earnings • May 01
First quarter 2026 earnings released: EPS: CN¥0.64 (vs CN¥0.70 in 1Q 2025) First quarter 2026 results: EPS: CN¥0.64 (down from CN¥0.70 in 1Q 2025). Revenue: CN¥5.38b (up 1.1% from 1Q 2025). Net income: CN¥224.6m (down 19% from 1Q 2025). Profit margin: 4.2% (down from 5.2% in 1Q 2025). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 4.4% p.a. on average during the next 2 years, compared to a 8.0% growth forecast for the Healthcare industry in China. Over the last 3 years on average, earnings per share has fallen by 7% per year whereas the company’s share price has fallen by 12% per year. Announcement • Apr 30
Guangxi LiuYao Group Co., Ltd, Annual General Meeting, May 20, 2026 Guangxi LiuYao Group Co., Ltd, Annual General Meeting, May 20, 2026, at 13:30 China Standard Time. Location: The Company's Meeting Room, Liuzhou, Guangxi China Announcement • Mar 30
Guangxi LiuYao Group Co., Ltd to Report Q1, 2026 Results on Apr 30, 2026 Guangxi LiuYao Group Co., Ltd announced that they will report Q1, 2026 results on Apr 30, 2026 Announcement • Dec 26
Guangxi LiuYao Group Co., Ltd to Report Fiscal Year 2025 Results on Apr 30, 2026 Guangxi LiuYao Group Co., Ltd announced that they will report fiscal year 2025 results on Apr 30, 2026 Price Target Changed • Nov 22
Price target decreased by 10% to CN¥21.70 Down from CN¥24.16, the current price target is provided by 1 analyst. New target price is 22% above last closing price of CN¥17.74. Stock is down 3.2% over the past year. The company is forecast to post earnings per share of CN¥1.94 for next year compared to CN¥2.21 last year. Reported Earnings • Nov 02
Third quarter 2025 earnings released: EPS: CN¥0.55 (vs CN¥0.63 in 3Q 2024) Third quarter 2025 results: EPS: CN¥0.55 (down from CN¥0.63 in 3Q 2024). Revenue: CN¥5.46b (up 2.0% from 3Q 2024). Net income: CN¥216.4m (down 14% from 3Q 2024). Profit margin: 4.0% (down from 4.7% in 3Q 2024). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 3.6% p.a. on average during the next 3 years, compared to a 9.0% growth forecast for the Healthcare industry in China. Over the last 3 years on average, earnings per share has increased by 3% per year whereas the company’s share price has remained flat. Announcement • Sep 30
Guangxi LiuYao Group Co., Ltd to Report Q3, 2025 Results on Oct 30, 2025 Guangxi LiuYao Group Co., Ltd announced that they will report Q3, 2025 results on Oct 30, 2025 Announcement • Jun 30
Guangxi LiuYao Group Co., Ltd to Report First Half, 2025 Results on Aug 29, 2025 Guangxi LiuYao Group Co., Ltd announced that they will report first half, 2025 results on Aug 29, 2025 Declared Dividend • May 25
Dividend increased to CN¥0.75 Dividend of CN¥0.75 is 25% higher than last year. Ex-date: 29th May 2025 Payment date: 29th May 2025 Dividend yield will be 4.4%, which is higher than the industry average of 1.9%. Sustainability & Growth Dividend is well covered by both earnings (36% earnings payout ratio) and cash flows (43% cash payout ratio). The dividend has increased by an average of 20% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. EPS is expected to grow by 32% over the next 3 years, which should provide support to the dividend and adequate earnings cover. Reported Earnings • May 02
First quarter 2025 earnings released: EPS: CN¥0.70 (vs CN¥0.83 in 1Q 2024) First quarter 2025 results: EPS: CN¥0.70 (down from CN¥0.83 in 1Q 2024). Revenue: CN¥5.32b (down 7.9% from 1Q 2024). Net income: CN¥277.3m (down 7.7% from 1Q 2024). Profit margin: 5.2% (in line with 1Q 2024). Revenue is forecast to grow 7.0% p.a. on average during the next 3 years, compared to a 10.0% growth forecast for the Healthcare industry in China. Over the last 3 years on average, earnings per share has increased by 11% per year but the company’s share price has only increased by 4% per year, which means it is significantly lagging earnings growth. Board Change • Apr 20
Less than half of directors are independent There are 5 new directors who have joined the board in the last 3 years. Of these new board members, 3 were independent directors. The company's board is composed of: 3 independent directors. 4 non-independent directors. Independent Director Jianhong Tao was the last independent director to join the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Announcement • Mar 28
Guangxi LiuYao Group Co., Ltd to Report Q1, 2025 Results on Apr 29, 2025 Guangxi LiuYao Group Co., Ltd announced that they will report Q1, 2025 results on Apr 29, 2025 Reported Earnings • Mar 27
Full year 2024 earnings: EPS and revenues miss analyst expectations Full year 2024 results: EPS: CN¥2.21. Revenue: CN¥21.2b (up 1.8% from FY 2023). Net income: CN¥854.9m (flat on FY 2023). Profit margin: 4.0% (down from 4.1% in FY 2023). The decrease in margin was driven by higher expenses. Revenue missed analyst estimates by 5.1%. Earnings per share (EPS) also missed analyst estimates by 8.1%. Revenue is forecast to grow 5.1% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Healthcare industry in China. Announcement • Mar 27
Guangxi LiuYao Group Co., Ltd, Annual General Meeting, Apr 18, 2025 Guangxi LiuYao Group Co., Ltd, Annual General Meeting, Apr 18, 2025, at 13:30 China Standard Time. Location: The Company's Meeting Room, Liuzhou, Guangxi China Announcement • Dec 27
Guangxi LiuYao Group Co., Ltd to Report Fiscal Year 2024 Results on Mar 29, 2025 Guangxi LiuYao Group Co., Ltd announced that they will report fiscal year 2024 results on Mar 29, 2025 Reported Earnings • Oct 31
Third quarter 2024 earnings released: EPS: CN¥0.63 (vs CN¥0.64 in 3Q 2023) Third quarter 2024 results: EPS: CN¥0.63. Revenue: CN¥5.35b (up 1.5% from 3Q 2023). Net income: CN¥251.7m (up 8.7% from 3Q 2023). Profit margin: 4.7% (up from 4.4% in 3Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Healthcare industry in China. Announcement • Sep 30
Guangxi LiuYao Group Co., Ltd to Report Q3, 2024 Results on Oct 30, 2024 Guangxi LiuYao Group Co., Ltd announced that they will report Q3, 2024 results on Oct 30, 2024 Valuation Update With 7 Day Price Move • Sep 27
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to CN¥17.39, the stock trades at a forward P/E ratio of 7x. Average forward P/E is 15x in the Healthcare industry in China. Total returns to shareholders of 16% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥24.97 per share. Reported Earnings • Aug 29
Second quarter 2024 earnings released: EPS: CN¥0.42 (vs CN¥0.50 in 2Q 2023) Second quarter 2024 results: EPS: CN¥0.42 (down from CN¥0.50 in 2Q 2023). Revenue: CN¥4.87b (down 2.8% from 2Q 2023). Net income: CN¥163.8m (down 9.9% from 2Q 2023). Profit margin: 3.4% (down from 3.6% in 2Q 2023). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Healthcare industry in China. Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings. Buy Or Sell Opportunity • Aug 26
Now 21% overvalued Over the last 90 days, the stock has fallen 27% to CN¥16.11. The fair value is estimated to be CN¥13.32, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 9.5% over the last 3 years. Earnings per share has grown by 12%. Revenue is forecast to grow by 24% in 2 years. Earnings are forecast to grow by 45% in the next 2 years. Announcement • Jun 28
Guangxi LiuYao Group Co., Ltd to Report First Half, 2024 Results on Aug 29, 2024 Guangxi LiuYao Group Co., Ltd announced that they will report first half, 2024 results on Aug 29, 2024 Declared Dividend • Jun 06
Dividend increased to CN¥0.60 Dividend of CN¥0.60 is 18% higher than last year. Ex-date: 11th June 2024 Payment date: 11th June 2024 Dividend yield will be 2.8%, which is higher than the industry average of 1.9%. Sustainability & Growth Dividend is covered by both earnings (24% earnings payout ratio) and cash flows (56% cash payout ratio). The dividend has increased by an average of 19% per year over the past 9 years and payments have been stable during that time. EPS is expected to grow by 62% over the next 3 years, which should provide support to the dividend and adequate earnings cover. New Risk • Apr 27
New major risk - Financial position The company's debt is not well covered by operating cash flow. Operating cash flow to total debt ratio: 12% This is considered a major risk. If the company's operating cash flows are too small relative to the size of their debt, it increases their balance sheet risk. The company has less cash from operations to cover its expenses from servicing large debt and it increases the risk of liquidity issues. It also extends the time it would take for the company to pay back the debt in full, meaning it may not be able to easily pay it all off in a distress scenario. Currently, the following risks have been identified for the company: Major Risk Debt is not well covered by operating cash flow (12% operating cash flow to total debt). Minor Risk Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Reported Earnings • Apr 27
First quarter 2024 earnings released: EPS: CN¥0.83 (vs CN¥0.72 in 1Q 2023) First quarter 2024 results: EPS: CN¥0.83 (up from CN¥0.72 in 1Q 2023). Revenue: CN¥5.77b (up 8.2% from 1Q 2023). Net income: CN¥300.3m (up 15% from 1Q 2023). Profit margin: 5.2% (up from 4.9% in 1Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 10% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Healthcare industry in China. Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has remained flat, which means it is significantly lagging earnings. Announcement • Apr 27
Guangxi LiuYao Group Co., Ltd, Annual General Meeting, May 17, 2024 Guangxi LiuYao Group Co., Ltd, Annual General Meeting, May 17, 2024, at 13:30 China Standard Time. Location: The Company's Meeting Room, Liuzhou, Guangxi China Announcement • Mar 29
Guangxi LiuYao Group Co., Ltd to Report Q1, 2024 Results on Apr 26, 2024 Guangxi LiuYao Group Co., Ltd announced that they will report Q1, 2024 results on Apr 26, 2024 Reported Earnings • Mar 21
Full year 2023 earnings released: EPS: CN¥2.34 (vs CN¥1.94 in FY 2022) Full year 2023 results: EPS: CN¥2.34 (up from CN¥1.94 in FY 2022). Revenue: CN¥20.8b (up 9.2% from FY 2022). Net income: CN¥846.8m (up 21% from FY 2022). Profit margin: 4.1% (up from 3.7% in FY 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 11% p.a. on average during the next 2 years, compared to a 16% growth forecast for the Healthcare industry in China. Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has only increased by 1% per year, which means it is significantly lagging earnings growth. Valuation Update With 7 Day Price Move • Feb 12
Investor sentiment improves as stock rises 15% After last week's 15% share price gain to CN¥17.95, the stock trades at a forward P/E ratio of 7x. Average forward P/E is 16x in the Healthcare industry in China. Total loss to shareholders of 7.1% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥11.28 per share. Announcement • Dec 30
Guangxi LiuYao Group Co., Ltd to Report Fiscal Year 2023 Results on Apr 26, 2024 Guangxi LiuYao Group Co., Ltd announced that they will report fiscal year 2023 results on Apr 26, 2024 Reported Earnings • Oct 26
Third quarter 2023 earnings released: EPS: CN¥0.64 (vs CN¥0.57 in 3Q 2022) Third quarter 2023 results: EPS: CN¥0.64 (up from CN¥0.57 in 3Q 2022). Revenue: CN¥5.27b (up 5.0% from 3Q 2022). Net income: CN¥231.6m (up 12% from 3Q 2022). Profit margin: 4.4% (up from 4.1% in 3Q 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Healthcare industry in China. Over the last 3 years on average, earnings per share has increased by 3% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings. Announcement • Sep 30
Guangxi LiuYao Group Co., Ltd to Report Q3, 2023 Results on Oct 26, 2023 Guangxi LiuYao Group Co., Ltd announced that they will report Q3, 2023 results on Oct 26, 2023 Price Target Changed • Sep 01
Price target decreased by 24% to CN¥25.19 Down from CN¥33.09, the current price target is provided by 1 analyst. New target price is 22% above last closing price of CN¥20.67. Stock is up 25% over the past year. The company is forecast to post earnings per share of CN¥2.32 for next year compared to CN¥1.94 last year. Reported Earnings • Aug 29
Second quarter 2023 earnings released: EPS: CN¥0.50 (vs CN¥0.41 in 2Q 2022) Second quarter 2023 results: EPS: CN¥0.50 (up from CN¥0.41 in 2Q 2022). Revenue: CN¥5.01b (up 14% from 2Q 2022). Net income: CN¥181.9m (up 23% from 2Q 2022). Profit margin: 3.6% (up from 3.4% in 2Q 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 10% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Healthcare industry in China. Over the last 3 years on average, earnings per share has remained flat but the company’s share price has fallen by 7% per year, which means it is significantly lagging earnings. Buying Opportunity • Aug 07
Now 22% undervalued after recent price drop Over the last 90 days, the stock is down 17%. The fair value is estimated to be CN¥25.68, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 8.9% over the last 3 years. Earnings per share has declined by 3.4%. Revenue is forecast to grow by 24% in 2 years. Earnings is forecast to grow by 44% in the next 2 years. Valuation Update With 7 Day Price Move • Jun 30
Investor sentiment improves as stock rises 22% After last week's 22% share price gain to CN¥24.71, the stock trades at a forward P/E ratio of 10x. Average forward P/E is 17x in the Healthcare industry in China. Total returns to shareholders of 12% over the past three years. Announcement • Jun 28
Guangxi LiuYao Group Co., Ltd to Report First Half, 2023 Results on Aug 29, 2023 Guangxi LiuYao Group Co., Ltd announced that they will report first half, 2023 results on Aug 29, 2023 Buying Opportunity • Jun 21
Now 21% undervalued after recent price drop Over the last 90 days, the stock is down 14%. The fair value is estimated to be CN¥25.51, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 8.9% over the last 3 years. Earnings per share has declined by 3.4%. Revenue is forecast to grow by 25% in 2 years. Earnings is forecast to grow by 46% in the next 2 years. Reported Earnings • Apr 21
First quarter 2023 earnings released: EPS: CN¥0.72 (vs CN¥0.61 in 1Q 2022) First quarter 2023 results: EPS: CN¥0.72 (up from CN¥0.61 in 1Q 2022). Revenue: CN¥5.33b (up 11% from 1Q 2022). Net income: CN¥261.1m (up 18% from 1Q 2022). Profit margin: 4.9% (up from 4.6% in 1Q 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Healthcare industry in China. Over the last 3 years on average, earnings per share has fallen by 3% per year whereas the company’s share price has fallen by 1% per year. Reported Earnings • Mar 01
Full year 2022 earnings released: EPS: CN¥1.91 (vs CN¥1.56 in FY 2021) Full year 2022 results: EPS: CN¥1.91 (up from CN¥1.56 in FY 2021). Revenue: CN¥19.1b (up 11% from FY 2021). Net income: CN¥692.3m (up 23% from FY 2021). Profit margin: 3.6% (up from 3.3% in FY 2021). The increase in margin was driven by higher revenue. Revenue is forecast to grow 11% p.a. on average during the next 2 years, compared to a 13% growth forecast for the Healthcare industry in China. Over the last 3 years on average, earnings per share has fallen by 6% per year whereas the company’s share price has fallen by 1% per year. Announcement • Nov 16
Guangxi LiuYao Group Co., Ltd (SHSE:603368) announces an Equity Buyback for CNY 100 million worth of its shares. Guangxi LiuYao Group Co., Ltd (SHSE:603368) announces a share repurchase program. Under the program, the company will repurchase up to CNY 100 million worth of its shares. The shares will be repurchased at a price of not more than CNY 26 per share. The shares purchased will be used for the company's equity incentive plan. The program will be valid for 6 months. Board Change • Nov 16
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. No highly experienced directors. 3 independent directors (4 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Reported Earnings • Oct 27
Third quarter 2022 earnings released: EPS: CN¥0.57 (vs CN¥0.47 in 3Q 2021) Third quarter 2022 results: EPS: CN¥0.57 (up from CN¥0.47 in 3Q 2021). Revenue: CN¥5.02b (up 10% from 3Q 2021). Net income: CN¥206.2m (up 22% from 3Q 2021). Profit margin: 4.1% (up from 3.7% in 3Q 2021). The increase in margin was driven by higher revenue. Revenue is forecast to grow 9.7% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Healthcare industry in China. Over the last 3 years on average, earnings per share has fallen by 7% per year whereas the company’s share price has fallen by 10% per year. Reported Earnings • Apr 28
First quarter 2022 earnings: EPS misses analyst expectations First quarter 2022 results: EPS: CN¥0.61 (up from CN¥0.57 in 1Q 2021). Revenue: CN¥4.81b (up 16% from 1Q 2021). Net income: CN¥220.9m (up 6.4% from 1Q 2021). Profit margin: 4.6% (down from 5.0% in 1Q 2021). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 20%. Over the next year, revenue is forecast to grow 11%, compared to a 21% growth forecast for the industry in China. Over the last 3 years on average, earnings per share has fallen by 2% per year but the company’s share price has fallen by 17% per year, which means it is performing significantly worse than earnings. Price Target Changed • Apr 27
Price target decreased to CN¥23.53 Down from CN¥27.79, the current price target is provided by 1 analyst. New target price is 67% above last closing price of CN¥14.06. Stock is down 38% over the past year. The company is forecast to post earnings per share of CN¥1.81 for next year compared to CN¥1.56 last year. Board Change • Apr 27
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 12 experienced directors. No highly experienced directors. 5 independent directors (7 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Reported Earnings • Apr 03
Full year 2021 earnings: EPS misses analyst expectations Full year 2021 results: EPS: CN¥1.56 (down from CN¥1.96 in FY 2020). Revenue: CN¥17.1b (up 9.4% from FY 2020). Net income: CN¥563.8m (down 21% from FY 2020). Profit margin: 3.3% (down from 4.5% in FY 2020). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 20%. Over the next year, revenue is forecast to grow 12%, compared to a 20% growth forecast for the industry in China. Over the last 3 years on average, earnings per share has increased by 2% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings. Valuation Update With 7 Day Price Move • Mar 22
Investor sentiment improved over the past week After last week's 17% share price gain to CN¥19.24, the stock trades at a forward P/E ratio of 9x. Average forward P/E is 17x in the Healthcare industry in China. Total loss to shareholders of 3.3% over the past three years. Valuation Update With 7 Day Price Move • Jan 24
Investor sentiment deteriorated over the past week After last week's 17% share price decline to CN¥17.91, the stock trades at a forward P/E ratio of 8x. Average forward P/E is 15x in the Healthcare industry in China. Total returns to shareholders of 1.7% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥17.46 per share. Valuation Update With 7 Day Price Move • Dec 31
Investor sentiment improved over the past week After last week's 17% share price gain to CN¥19.04, the stock trades at a forward P/E ratio of 8x. Average forward P/E is 16x in the Healthcare industry in China. Total returns to shareholders of 12% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥16.96 per share. Reported Earnings • Oct 27
Third quarter 2021 earnings released: EPS CN¥0.47 (vs CN¥0.59 in 3Q 2020) The company reported a soft third quarter result with weaker earnings and profit margins, although revenues improved. Third quarter 2021 results: Revenue: CN¥4.56b (up 9.0% from 3Q 2020). Net income: CN¥169.0m (down 21% from 3Q 2020). Profit margin: 3.7% (down from 5.1% in 3Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has fallen by 7% per year, which means it is significantly lagging earnings. Reported Earnings • Aug 19
Second quarter 2021 earnings released: EPS CN¥0.34 (vs CN¥0.58 in 2Q 2020) The company reported a soft second quarter result with weaker earnings and profit margins, although revenues improved. Second quarter 2021 results: Revenue: CN¥4.16b (up 5.2% from 2Q 2020). Net income: CN¥121.7m (down 42% from 2Q 2020). Profit margin: 2.9% (down from 5.3% in 2Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings. Reported Earnings • Mar 30
Full year 2020 earnings released: EPS CN¥1.96 (vs CN¥1.90 in FY 2019) The company reported a solid full year result with improved earnings and revenues, although profit margins were weaker. Full year 2020 results: Revenue: CN¥15.7b (up 5.5% from FY 2019). Net income: CN¥711.7m (up 3.8% from FY 2019). Profit margin: 4.5% (down from 4.6% in FY 2019). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings. Announcement • Mar 05
Guangxi Liuzhou Pharmaceutical Co., Ltd. to Report Fiscal Year 2020 Results on Mar 30, 2021 Guangxi Liuzhou Pharmaceutical Co., Ltd. announced that they will report fiscal year 2020 results on Mar 30, 2021 Is New 90 Day High Low • Jan 11
New 90-day low: CN¥20.16 The company is down 15% from its price of CN¥23.81 on 13 October 2020. The Chinese market is up 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Healthcare industry, which is up 12% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥69.33 per share. Is New 90 Day High Low • Dec 24
New 90-day low: CN¥21.59 The company is down 8.0% from its price of CN¥23.36 on 25 September 2020. The Chinese market is up 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Healthcare industry, which is up 15% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥71.50 per share. Major Estimate Revision • Dec 16
Analysts lower EPS estimates to CN¥2.31 The 2020 consensus revenue estimate was lowered from CN¥17.3b to CN¥17.0b. Earning per share (EPS) estimate was also lowered from CN¥2.59 to CN¥2.31 for the same period. Net income is expected to grow by 29% next year compared to 18% growth forecast for the Healthcare industry in China. The consensus price target was lowered from CN¥38.94 to CN¥31.29. Share price stayed mostly flat at CN¥22.75 over the past week. Reported Earnings • Oct 28
Third quarter earnings released Over the last 12 months the company has reported total profits of CN¥746.4m, up 9.0% from the prior year. Total revenue was CN¥15.5b over the last 12 months, up 9.8% from the prior year. Is New 90 Day High Low • Oct 20
New 90-day low: CN¥22.97 The company is down 9.0% from its price of CN¥25.20 on 22 July 2020. The Chinese market is flat over the last 90 days, indicating the company underperformed over that time. It also underperformed the Healthcare industry, which is up 10.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥16.62 per share. Is New 90 Day High Low • Oct 01
New 90-day low: CN¥23.29 The company is down 3.0% from its price of CN¥24.00 on 03 July 2020. The Chinese market is up 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Healthcare industry, which is up 13% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥13.13 per share. Announcement • Jul 08
Guangxi Liuzhou Pharmaceutical Co., Ltd. to Report First Half, 2020 Results on Aug 20, 2020 Guangxi Liuzhou Pharmaceutical Co., Ltd. announced that they will report first half, 2020 results on Aug 20, 2020